"When a senior Vice President of Clinical Development overseeing the clinical development programs for RVX-208 (apabetalone) sells his holdings it raises concern with some retail investors. Presumably, he is a well-paid individual and when he or any other senior manager sells shares at this stage of the game, does not bode well. "

Here we go again. All that's nothing but a fabrication.

Dang, I'm polite about it.